Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: lipid emulsion, nanostructured lipid carriers and solid lipid nanoparticles

References

• Bose S, Ravis WR, Lin YJ, Zhang L, Hofmann GA, Banga AK. Electrically-assisted transdermal delivery of buprenorphine. J Contr Rel 2001; 73: 197–203
   PubMed Web of Science ®Google Scholar
• Bunjes H, Koch MHJ, Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci 2003; 92: 1509–1520
   PubMed Web of Science ®Google Scholar
• Chen H, Chang X, Du D, Liu W, Liu J, Weng T, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Contr Rel 2006; 110: 296–306
   PubMed Web of Science ®Google Scholar
• Chin LS, Huang KL, Liu KS, Chu CC, Tzeng JI, Ho ST, et al. An esterification method for synthesizing prodrugs of buprenorphine. Acta Anaesthesiol Taiwanica 2005; 43: 223–229
   PubMedGoogle Scholar
• Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63: 1999–2010
   PubMed Web of Science ®Google Scholar
• Fang JY, Hung CF, Hwang TL, Huang YL. Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. J Drug Target 2005; 13: 19–27
   PubMed Web of Science ®Google Scholar
• Fang JY, Hwang TL, Huang YL. Liposomes as vehicles for enhancing drug delivery via skin routes. Curr Nanosci 2006; 2: 55–70
   Web of Science ®Google Scholar
• Fang JY, Leu YL. Prodrug strategy for enhancing drug delivery via skin. Curr Drug Discov Technol 2006; 3: 211–224
   PubMedGoogle Scholar
• Hammell DC, Stolarczyk EI, Klausner M, Hamad MO, Crooks PA, Stinchcomb AL. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent. J Pharm Sci 2005; 94: 828–836
   PubMed Web of Science ®Google Scholar
• Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm 2006; 314: 83–89
   PubMed Web of Science ®Google Scholar
• Imoto H, Zhou Z, Stinchcomb AL, Flynn GL. Transdermal prodrug concepts: Permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles. Biol Pharm Bull 1996; 19: 263–267
   PubMed Web of Science ®Google Scholar
• Jenning V, Thünemann AF, Gohla SH. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 2000; 199: 167–177
   PubMed Web of Science ®Google Scholar
• Juntunen J, Majumdar S, Sloan KB. The effect of water solubility of solutes on their flux through human skin in vitro: A prodrug database integrated into the extended Flynn database. Int J Pharm 2008; 351: 92–103
   PubMedGoogle Scholar
• Küchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, Haag R, et al. Nanoparticles for skin penetration enhancement—a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm 2009, in press
   Google Scholar
• Kawaguchi T, Tsugane A, Higashide K, Endoh H, Hasegawa T, Kanno H, et al. Control of drug release with a combination of prodrug and polymer matrix: Antitumor activity and release profiles of 2. J Pharm Sci 1992; 81: 508–512
   PubMed Web of Science ®Google Scholar
• Kleppner SR, Patel R, McDonough J, Costantini LC. In-vitro and in-vivo characterization of a buprenorphine delivery system. J Pharm Pharmacol 2006; 58: 295–302
   PubMed Web of Science ®Google Scholar
• Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci 2006; 123–126: 369–385
   PubMed Web of Science ®Google Scholar
• Lipp R, Laurent H, Günther C, Riedl J, Esperling P, Täuber U. Prodrugs of gestodene for matrix-type transdermal drug delivery systems. Pharm Res 1998; 15: 1419–1424
   PubMed Web of Science ®Google Scholar
• Liu KS, Tzeng JI, Chen YW, Huang KL, Kuei CH, Wang JJ. Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect. Anesth Analg 2006; 102: 1445–1451
   PubMedGoogle Scholar
• Lombardi Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, et al. Lipid nanoparticles for skin penetration enhancement—correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Contr Rel 2005; 110: 151–163
   PubMed Web of Science ®Google Scholar
• Müller RH. Lipid nanoparticles: Recent advances. Adv Drug Deliv Rev 2007; 59: 522–530
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161–177
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54: S131–S155
   PubMed Web of Science ®Google Scholar
• Montenegro L, Carbone C, Maniscalco C, Lambusta D, Nicolosi G, Ventura CA, et al. In vitro evaluation of quercetin-3-O-acyl esters as topical prodrugs. Int J Pharm 2007; 336: 257–262
   PubMed Web of Science ®Google Scholar
• Ostacolo C, Marra F, Laneri S, Sacchi A, Nicoli S, Padula C, et al. α-Tocopherol pro-vitamins: Synthesis, hydrolysis and accumulation in rabbit ear skin. J Contr Rel 2004; 99: 403–413
   PubMed Web of Science ®Google Scholar
• Park I, Kim D, Song J, In CH, Jeong SW, Lee SH, et al. Buprederm™, a new transdermal delivery system of buprenorphine: Pharmacokinetic, efficacy and skin irritancy studies. Pharm Res 2008; 25: 1052–1062
   PubMed Web of Science ®Google Scholar
• Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, et al. Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int J Pharm 2008; 357: 295–304
   PubMed Web of Science ®Google Scholar
• Rautio J, Nevalainen T, Taipale H, Vepsälänen J, Gynther J, Laine K, et al. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur J Pharm Sci 2000; 11: 157–163
   PubMed Web of Science ®Google Scholar
• Schmid-Grendelmeier P, Pokorny R, Gasser UE, Richarz U. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr Med Res Opin 2006; 22: 501–509
   PubMed Web of Science ®Google Scholar
• Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004; 26: 1808–1820
   PubMed Web of Science ®Google Scholar
• Souto EB, Almeida AJ, Müller RH. Lipid nanoparticles (SLN®, NLC®) for cutaneous drug delivery: Structure, protection and skin effects. J Biomed Nanotechnol 2007; 3: 317–331
   Web of Science ®Google Scholar
• Stinchcomb AL, Dua R, Paliwal A, Woodard RW, Flynn GL. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm Res 1995; 12: 1526–1529
   PubMed Web of Science ®Google Scholar
• Stinchcomb AL, Paliwal A, Dua R, Imoto H, Woodard RW, Flynn GL. Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. Pharm Res 1996; 13: 1519–1523
   PubMed Web of Science ®Google Scholar
• Suppasansatorn P, Wang G, Conway BR, Wang W, Wang Y. Skin delivery potency and antitumor activities of temozolomide ester prodrugs. Cancer Lett 2006; 244: 42–52
   PubMed Web of Science ®Google Scholar
• Swenson J, Olgun S, Radjavi A, Kaur T, Reilly CM. Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice. Eur J Pharmacol 2007; 567: 67–76
   PubMedGoogle Scholar
• Thomas JD, Sloan KB. In vitro evaluation of alkylcarbonyloxymethyl (ACOM) ethers as novel prodrugs of phenols for topical delivery: ACOM prodrugs of acetaminophen. Int J Pharm 2008; 346: 80–88
   PubMedGoogle Scholar
• Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm 2004; 270: 119–125
   PubMed Web of Science ®Google Scholar
• Valjakka-Koskela R, Kirjavainen M, Monkkonen J, Urtti A, Kiesvaara J. Enhancement of percutaneous absorption of naproxen by phospholipids. Int J Pharm 1998; 175: 225–230
   Web of Science ®Google Scholar
• Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Contr Rel 2004; 95: 627–638
   PubMed Web of Science ®Google Scholar
• Wang JJ, Sung KC, Hu OYP, Yeh CH, Fang JY. Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. J Contr Rel 2006; 115: 140–149
   PubMed Web of Science ®Google Scholar
• Wang JJ, Sung KC, Yeh CH, Fang JY. The delivery and antinociceptive effects of morphine and its ester prodrugs from lipid emulsions. Int J Pharm 2008; 353: 95–104
   PubMedGoogle Scholar
• Wilding R, Davis SS, Rimoy GH, Rubin P, Kurihara-Bergstrom T, Tipnis V, et al. Pharmacokinetic evaluation of transdermal buprenorphine in man. Int J Pharm 1996; 132: 81–87
   Google Scholar